Biologic and immunologic characteristics of ovarian cancers that are associated with p53 autoantibodies

BACKGROUND: Autoantibodies (AAbs) against p53 develop in a fraction of patients with ovarian cancer, but the mechanisms underlying their development remain unknown. High-grade serous carcinoma (HGSC) is the most prevalent and lethal histotype, and nearly all HGSCs exhibit TP53 mutations, although only 20%-30% evoke anti-p53 AAbs. METHODS: Serum and tissue samples were analyzed from 174 patients with ovarian cancer who were included in the Danish Pelvic Mass/Gynecologic Ovarian Vulva Endometrial and Cervix Cancer study. RESULTS: Elevated levels of immunoglobulin G anti-p53 AAbs were detected in 30 patients, all with HGSC. Among the patients who had HGSC, elevated levels of anti-p53 AAbs were identified in 17% of those with early stage (I-II) disease and in 23% of those with late stage (III + IV) disease. Ninety-seven percent of samples with elevated anti-p53 AAbs had TP53 mutations, 93% had mutations restricted to the DNA-binding domain, and 89% had overexpression of p53 protein in tissue sections. Neither anti-p53 AAb levels nor p53 protein expression was associated with survival. Infiltration of CD20-positive/CD23-positive B cells and CD8-positive T cells correlated with anti-p53 AAbs, consistent with heightened immune activation. Increased immunoglobulin production appeared to be specific for p53 in that no correlation was observed between anti-p53 AAbs and human epididymis protein 4 antigen-AAb complexes. Absorption experiments have suggested that anti-p53 AAbs associated with HGSC are directed against epitopes on wild-type p53 protein. TP53 mutation and overexpression of p53 appear to be necessary, but not sufficient, for the induction of anti-p53 AAbs. CONCLUSIONS: Anti-p53 AAbs identify a distinct subset of TP53-mutant HGSC with an active tumor immune microenvironment and warrant further development as a biomarker for early detection.

Authors

Institutions

Publication Details

Journal
Cancer
Published
2026-11-13
DOI
https://doi.org/10.1002/cncr.70672
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Biologic and immunologic characteristics of ovarian cancers that are associated with p53 autoantibodies

Cuipeng Qiu, Karen S. Anderson, Robert C. Bast, Tim Svenstrup Poulsen et al.
Cancer
Ovarian cancer diagnosis and treatment
article

Biologic and immunologic characteristics of ovarian cancers that are associated with p53 autoantibodies

Cuipeng Qiu, Karen S. Anderson, Robert C. Bast, Tim Svenstrup Poulsen, Claus Høgdall, Zhen Lu, Wei‐Lei Yang, Hailing Yang, Estrid Høgdall
article en

Abstract

BACKGROUND: Autoantibodies (AAbs) against p53 develop in a fraction of patients with ovarian cancer, but the mechanisms underlying their development remain unknown. High-grade serous carcinoma (HGSC) is the most prevalent and lethal histotype, and nearly all HGSCs exhibit TP53 mutations, although only 20%-30% evoke anti-p53 AAbs. METHODS: Serum and tissue samples were analyzed from 174 patients with ovarian cancer who were included in the Danish Pelvic Mass/Gynecologic Ovarian Vulva Endometrial and Cervix Cancer study. RESULTS: Elevated levels of immunoglobulin G anti-p53 AAbs were detected in 30 patients, all with HGSC. Among the patients who had HGSC, elevated levels of anti-p53 AAbs were identified in 17% of those with early stage (I-II) disease and in 23% of those with late stage (III + IV) disease. Ninety-seven percent of samples with elevated anti-p53 AAbs had TP53 mutations, 93% had mutations restricted to the DNA-binding domain, and 89% had overexpression of p53 protein in tissue sections. Neither anti-p53 AAb levels nor p53 protein expression was associated with survival. Infiltration of CD20-positive/CD23-positive B cells and CD8-positive T cells correlated with anti-p53 AAbs, consistent with heightened immune activation. Increased immunoglobulin production appeared to be specific for p53 in that no correlation was observed between anti-p53 AAbs and human epididymis protein 4 antigen-AAb complexes. Absorption experiments have suggested that anti-p53 AAbs associated with HGSC are directed against epitopes on wild-type p53 protein. TP53 mutation and overexpression of p53 appear to be necessary, but not sufficient, for the induction of anti-p53 AAbs. CONCLUSIONS: Anti-p53 AAbs identify a distinct subset of TP53-mutant HGSC with an active tumor immune microenvironment and warrant further development as a biomarker for early detection.

CancerVol. 132(22)
The University of Texas MD Anderson Cancer Center (US), Herlev Hospital (DK), Copenhagen University Hospital (DK), Rigshospitalet (DK), Arizona State University (US)
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon